Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747843 | 0.78 | LMNA (0.40) | ALDH1A1TSHR | |
| SCHEMBL5414507 | 0.74 | ALDH1A1 (0.34) | MAPTALDH1A1HTTRAB9AGAA | |
| SCHEMBL5068751 | 0.69 | P2RX4 (0.42) | ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL2979170 | 0.68 | P2RX4 (0.42) | KMT2ATSHRMEN1GAA | |
| SCHEMBL7339446 | 0.68 | LMNA (0.40) | MAPTALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL7334705 | 0.68 | LMNA (0.51) | TSHR | |
| SCHEMBL15865153 | 0.68 | LMNA (0.40) | ALDH1A1TSHR | |
| SCHEMBL27285585 | 0.68 | LMNA (0.40) | ALDH1A1TSHR | |
| SCHEMBL8423850 | 0.67 | P2RX4 (0.37) | — | |
| SCHEMBL7775720 | 0.66 | KMT2A (0.67) | KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070027143-A1 | Novel substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. (HU) | 2007-02-01 | — | — | US | disclosed |
| US-6858605-B2 | Substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. (HU) | 2005-02-22 | — | — | US | disclosed |
| US-20040152693-A1 | Novel substituted 2,3-benzodiazepine derivatives | IVAX DRUG RESEARCH INSTITUTE, LTD. | 2004-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152693-A1 | Novel substituted 2,3-benzodiazepine derivatives | GABRB2, GABRB3, GABRA2 | MAPT 967/4885KDM4E 1878/4885ALDH1A1 844/4885 |
| US-20070027143-A1 | Novel substituted 2,3-benzodiazepine derivatives | GABRB2, GABRB3, GABRA2 | MAPT 967/4885KDM4E 1878/4885ALDH1A1 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.